Théa
Théa, announces the development of a structured roadmap to reduce its greenhouse gas emissions, in alignment with international climate objectives and the global ambition of carbon neutrality by 2045.
2/18/26
Innovation
Tsubota Laboratory announces the achievement of First Patient In (FPI) in the global Phase 2 clinical trial of TLM-003, an investigational eye drop developed to suppress myopia progression, marking a key milestone in its international clinical dev...
2/11/26
Théa
Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline.
12/4/25
Théa
Sepul Bio: Théa’s Innovative Unit Doses First in Phase 3 HYPERION Trial for LCA10
10/1/25
Pathology
/
Innovation
International
Corporate
New partnership Théa and Lenz Therapeutics
8/27/25
Théa
This year, ABAK® celebrating 30 years of innovation.
8/27/25